Moreover, we address how anti‐CD30 immunotherapy was developed and the impact of the anti‐CD30‐auristatin conjugate and anti‐CD30 CAR‐T cells in treating CD30‐expressing lymphomas. This evidence concerns the gene TNFRSF8 and lymphoma.